United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $571.22, for a total value of $5,426,590.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company's stock, valued at approximately $23,141,835.86. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
United Therapeutics Trading Up 0.0%
Shares of United Therapeutics stock opened at $571.35 on Friday. The stock has a 50 day moving average of $543.83 and a 200 day moving average of $497.42. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $607.89. The firm has a market cap of $25.04 billion, a PE ratio of 20.48, a PEG ratio of 1.62 and a beta of 0.75.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the prior year, the company earned $6.19 earnings per share. The firm's revenue was up 7.4% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund raised its position in United Therapeutics by 2.9% during the first quarter. Oregon Public Employees Retirement Fund now owns 8,840 shares of the biotechnology company's stock valued at $5,242,000 after purchasing an additional 251 shares during the period. Frank Rimerman Advisors LLC purchased a new stake in shares of United Therapeutics in the first quarter worth approximately $230,000. Swedbank AB raised its holdings in shares of United Therapeutics by 0.7% in the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company's stock worth $193,977,000 after buying an additional 2,350 shares during the period. Sage Rhino Capital LLC raised its holdings in shares of United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after buying an additional 23 shares during the period. Finally, DGS Capital Management LLC raised its holdings in shares of United Therapeutics by 22.9% in the first quarter. DGS Capital Management LLC now owns 1,034 shares of the biotechnology company's stock worth $613,000 after buying an additional 193 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts recently commented on UTHR shares. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. TD Cowen upped their price objective on United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research report on Monday, March 30th. Bank of America upped their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research report on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an "outperform" rating and a $700.00 price objective on the stock. Finally, Wells Fargo & Company upped their price objective on United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $601.50.
View Our Latest Research Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
